Ovid Therapeutics Inc.
OVIDNASDAQHealthcare● Active
$2.41
+$0.05(+1.91%)
Market Cap$317182148
P/E Ratio—
52W High$3.105
52W Low$0.272
Ovid Therapeutics Inc. (OVID) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OVID · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.25M | $0.57M | $0.39M | $1.50M | $208.38M |
| Cost of Revenue | $0.30M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $6.95M | $0.57M | $0.39M | $1.50M | $208.38M |
| Gross Margin %(computed) | 95.86% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $25.58M | $36.77M | $28.59M | $24.62M | $46.94M |
| G&A Expenses | $24.11M | $25.68M | $29.59M | $32.43M | $37.23M |
| Total Operating Expenses | $49.39M | $62.45M | $59.67M | $57.05M | $84.17M |
| Operating Income | ($42.44M) | ($61.88M) | ($59.28M) | ($55.55M) | $124.21M |
| Operating Margin %(computed) | -585.20% | — | — | — | 59.61% |
| Interest Income | $0.00M | $3.90M | $4.90M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($17.41M) | ($26.43M) | ($52.34M) | ($54.17M) | $124.16M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $1.33M |
| Net Income | ($17.41M) | ($26.43M) | ($52.34M) | ($54.17M) | $122.83M |
| Net Margin %(computed) | -240.13% | — | — | — | 58.95% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.24 | $-0.37 | $-0.74 | $-0.77 | $1.78 |
| Wtd Avg Shares | 73.74M | 70.91M | 70.58M | 70.42M | 67.48M |
| EBITDA | ($42.14M) | ($57.77M) | ($57.01M) | ($54.17M) | $124.45M |
| EBITDA Margin %(computed) | -581.07% | — | — | — | 59.72% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Ovid Therapeutics Inc. data
About Ovid Therapeutics Inc. (OVID) Income Statement
Ovid Therapeutics Inc. (OVID) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, OVID reported revenue of $0.01B, gross profit of $0.01B (gross margin 95.86%), and net income of ($0.02B) — a net profit margin of -240.13%.
Frequently asked questions
OVID · 4 questionsOvid Therapeutics Inc. (OVID) reported revenue of $0.01B for 2025, up 1181.3% year-over-year.
OVID revenueOVID salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09